ModernGraham Valuation

Company Name:

Centene Corp

Company Ticker Date of Analysis CNC

1/25/2017



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

Adequate Size of the Enterprise	Market Cap > \$2Bil	\$10,996,411,003	Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	0.86	Fail
3. Earnings Stability	Positive EPS for 10 years prior		Pass
Dividend Record	Dividend Payments for 10 years prior		Fail
E. Familiana Onweth	Increase of 33% in EPS in past 10 years using 3 year averages at	100.049/	D
Earnings Growth	beginning and end	190.94%	Pass

6. Moderate PEmg Ratio 27.69 Fail PEmg < 20 7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 1.97 Pass

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition Current Ratio > 1.5 0.86 Fail 2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 -2.95 Fail 3. Earnings Stability Positive EPS for 5 years prior Pass Fail 4. Dividend Record Currently Pays Dividend 5. Earnings Growth EPSmg greater than 5 years ago Pass

Score

Suitability

Defensive No Enterprising

Stage 2: Determination of Intrinsic Value

EPSma \$2.33 MG Growth Estimate 15.00% MG Value \$89.65 MG Value based on 3% Growth \$33.77 MG Value based on 0% Growth \$19.79 Market Implied Growth Rate 9.59%

MG Opinion

Current Price \$64.48 % of Intrinsic Value 71.92%

Opinion Undervalued

MG Grade C-

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -\$35.39 Graham Number \$45.39 PEmg 27 69 Current Ratio 0.86 PB Ratio 1.97 Current Dividend \$0.00 Dividend Yield 0.00% Number of Consecutive Years of Dividend 0

Useful Links: ModernGraham tagged articles

Morningstar Google Finance MSN Money Yahoo Finance Seeking Alpha **GuruFocus SEC Filings**

EPS History	·	EPSmg History	
Next Fiscal Year			
Estimate	•	Next Fiscal Year Estimate	\$2.33
Dec2015	\$2.88	Dec2015	\$1.93
Dec2014	\$2.25	Dec2014	\$1.35
Dec2013	\$1.47	Dec2013	\$0.90
Dec2012	\$0.02	Dec2012	\$0.67
Dec2011	\$1.06	Dec2011	\$0.97
Dec2010	\$0.94	Dec2010	\$0.83
Dec2009	\$0.95	Dec2009	\$0.70
Dec2008	\$0.94	Dec2008	\$0.55
Dec2007	\$0.82	Dec2007	\$0.36
Dec2006	-\$0.51	Dec2006	\$0.18
Dec2005	\$0.62	Dec2005	\$0.50
Dec2004	\$0.51	Dec2004	\$0.41
Dec2003	\$0.44	Dec2003	\$0.20
Dec2002	\$0.37	Dec2002	-\$0.01
Dec2001	\$0.27	Dec2001	-\$0.23
Dec2000	\$0.19	Dec2000	-\$0.43
Dec1999	-\$1.83	Balance Sheet Information	9/1/2016
Dec1998	\$0.00	Total Current Assets	\$7,755,000,000
Dec1997	\$0.00	Total Current Liabilities	\$9,023,000,000
Dec1996	\$0.00	Long-Term Debt	\$3,744,000,000
		Total Assets	\$19,634,000,000
		Intangible Assets	\$6,296,000,000
		Total Liabilities	\$13,924,000,000
		Shares Outstanding (Diluted Average)	174,312,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

ModernGraham posts about the company

#N/A

Other ModernGraham posts about related companies Invacare Corporation Valuation – Initial Coverage \$IVC

Becton Dickinson and Co Valuation – January 2017 \$BDX

Select Medical Holdings Corp Valuation – Initial Coverage \$SEM

Chemed Corporation Valuation – Initial Coverage \$CHE

<u>Inogen Inc Valuation – Initial Coverage \$INGN</u>

<u>Surgical Care Affiliates Inc Valuation – Initial Coverage \$SCAI</u>

Thermo Fisher Scientific Inc Valuation – December 2016 \$TMO

Illumina Inc Valuation - Initial Coverage \$ILMN

<u>Thermo Fisher Scientific Inc Valuation – November 2016 \$TMO</u>

Waters Corporation Valuation - November 2016 \$WAT